GlassScriptPhysician profile
Nicholas Hinds
NPI 1346689551
$10,941.79
in general payments reported to CMS, 2019-2025
33 companies · $2,954 in 2025
The $2,954 reported for 2025 was more than what 82% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $200 · 2021: $145 · 2022: $2,307 · 2023: $2,693 · 2024: $2,493 · 2025: $2,954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,138.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,569.86 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,639.05 | 2020-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,085.86 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Genzyme Corporation | $921.92 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $503.98 | 2022-2025 | Dupixent |
| Insmed, INC. | $466.88 | 2022-2025 | Arikayce |
| Jazz Pharmaceuticals INC. | $385.34 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $322.84 | 2020-2025 | Aralast |
| Amgen INC. | $248.01 | 2022-2025 | Tezspire |
| Verona Pharma, INC. | $198.92 | 2025 | Ohtuvayre |
| Harmony Biosciences LLC | $195.37 | 2023-2025 | Wakix |
| Philips North America LLC | $194.18 | 2022-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Mylan Specialty L.P. | $192.88 | 2022-2024 | Yupelri |
| Ani Pharmaceuticals, INC. | $161.12 | 2023-2025 | Purified Cortrophin Gel |
| United Therapeutics Corporation | $159.10 | 2023-2025 | Tyvaso, Tyvaso |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $85.10 | 2025 | Prolastin-C Liquid |
| Sanofi-Aventis U.S. LLC | $79.99 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $77.57 | 2021-2023 | Opsumit, Uptravi |
| Electromed, INC. | $70.52 | 2025 | Smartvest |
| Mallinckrodt Hospital Products INC. | $55.47 | 2025 | Acthar |
| Inspire Medical Systems, INC. | $43.60 | 2024-2025 | Inspire |
| Sumitomo Pharma America, INC. | $41.07 | 2023 | Gemtesa |
| Lilly USA, LLC | $38.76 | 2025 | Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $36.74 | 2021-2022 | |
| Viatris Specialty LLC | $34.99 | 2025 | Yupelri |
| Allergan, INC. | $22.21 | 2019 | |
| Tactile Systems Technology INC | $21.34 | 2024 | Flexitouch Plus, Entre Plus |
| Phadia US INC. | $20.81 | 2024 | Immunocap |
| Vifor Pharma, INC. | $16.12 | 2024 | Zemaira |
| Shire North American Group INC | $14.34 | 2019 | |
| Merck Sharp & Dohme LLC | $13.79 | 2020 | |
| Shionogi INC | $13.11 | 2022 | |
| Genentech USA, INC. | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Hinds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.